Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25967589 | 0.82 | PLA2G2A (0.43) | PLA2G10PLA2G2ATLR2 | |
| SCHEMBL10043029 | 0.82 | PLA2G2A (0.43) | PLA2G10PLA2G2ATLR2 | |
| SCHEMBL22406078 | 0.81 | PLA2G10 (0.38) | CETPCSNK1EPLA2G10PLA2G2ACTRC | |
| SCHEMBL28998085 | 0.80 | CETP (0.45) | CETPCSNK1ECTRC | |
| SCHEMBL29770041 | 0.80 | CA2 (0.33) | CSNK1E | |
| SCHEMBL29770034 | 0.80 | CA2 (0.33) | CSNK1E | |
| SCHEMBL29770030 | 0.80 | CA2 (0.33) | CSNK1E | |
| SCHEMBL16830095 | 0.80 | CA2 (0.33) | CSNK1E | |
| SCHEMBL27089882 | 0.78 | L3MBTL1 (0.40) | CETPCSNK1EPLA2G10PLA2G2ATLR2 | |
| SCHEMBL31411073 | 0.78 | BTN3A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0639977-A4 | LIPID-A ANALOGS: NEW MONOSACCHARIDE AND DISACCHARIDE INTERMEDIATES FOR ELICITING THERAPEUTIC ANTIBODIES AND FOR ANTITUMOR AND ANTIVIRAL ACTIVITIES. | IGEN INC (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5597573-A | ADMINISTERING AS AN IMMUNOGEN | IGEN, INC. (US) | 1997-01-28 | — | — | US | disclosed |
| US-5593969-A | TREATMENT OF SEPTICEMIA | IGEN INCORPORATED (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0639977-A1 | LIPID-A ANALOGS: NEW MONOSACCHARIDE AND DISACCHARIDE INTERMEDIATES FOR ELICITING THERAPEUTIC ANTIBODIES AND FOR ANTITUMOR AND ANTIVIRAL ACTIVITIES | IGEN, INC. (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993019761-A1 | LIPID-A ANALOGS: NEW MONOSACCHARIDE AND DISACCHARIDE INTERMEDIATES FOR ELICITING THERAPEUTIC ANTIBODIES AND FOR ANTITUMOR AND ANTIVIRAL ACTIVITIES | IGEN, INC. (US) | 1993-10-14 | — | — | WO | disclosed |